key: cord-0820385-qbp5nid8 authors: Voshaar, Thomas; Stais, Patrick; Köhler, Dieter; Dellweg, Dominic title: Conservative management of Covid 19 associated hypoxemia date: 2021-01-28 journal: ERJ Open Res DOI: 10.1183/23120541.00026-2021 sha: 82b9129bcc070ab2476f50d53fc060d27b79936f doc_id: 820385 cord_uid: qbp5nid8 BACKGROUND: Invasive mechanical ventilation of hypoxemic Covid 19 patients is associated with mortality rates of more than 50%. We evaluated clinical outcome data of two hospitals that agreed on a predefined protocol for restrictive use of invasive ventilation where the decision to intubate was based on the clinical presentation and oxygen content rather than on the degree of hypoxemia. METHOD: Data analysis of patients with positive PCR-testing for SARS-CoV-2, typical history, and symptoms and pulmonary infiltrates who exhibited oxygen saturation values of less than 93%. RESULTS: We identified 78 patients who met the inclusion criteria. The SaO2 nadir was 84.4±6.5% for the whole group. Fifty-three patients (68%) received nasal oxygen (group1), 17 patients (22%) were treated with nasal high-flow, CPAP, non-invasive ventilation, or a combination thereof (group 2) and 8 patients (10%) were intubated (group 3). The Horovitz index was 216±8 for group 1, 157±13 for group 2, and 106±15 for group 3. Oxygen content was 14.5±2.5, 13.4±1.9, and 11.6±2.6 mL·dL(−1) for the three respective groups. Overall mortality was 7.7%, the mortality of intubated patients was 50%. 93% of patients could be discharged on room air. CONCLUSION: Permissive hypoxemia where decisions for the level of respiratory therapy were based on the clinical presentation and oxygen content resulted in low intubation rates, low overall mortality, and a low number of patients who require oxygen after discharge. Background: Invasive mechanical ventilation of hypoxemic Covid 19 patients is associated with mortality rates of more than 50 %. We evaluated clinical outcome data of two hospitals that agreed on a predefined protocol for restrictive use of invasive ventilation where the decision to intubate was based on the clinical presentation and oxygen content rather than on the degree of hypoxemia. Data analysis of patients with positive PCR-testing for SARS-CoV-2, typical history, and symptoms and pulmonary infiltrates who exhibited oxygen saturation values of less than 93 %. We identified 78 patients who met the inclusion criteria. The SaO2 nadir was 84.4 ± 6.5 % for the whole group. Fifty-three patients (68%) received nasal oxygen (group1), 17 patients (22%) were treated with nasal high-flow, CPAP, non-invasive ventilation, or a combination thereof (group 2) and 8 patients (10%) were intubated (group 3). The Horovitz index was 216 ± 8 for group 1, 157 ± 13 for group 2, and 106 ± 15 for group 3. Oxygen content was 14.5 ± 2.5, 13.4 ± 1.9, and 11.6 ± 2.6 ml/dl for the three respective groups. Overall mortality was 7.7 %, the mortality of intubated patients was 50 %. 93 % of patients could be discharged on room air. Permissive hypoxemia where decisions for the level of respiratory therapy were based on the clinical presentation and oxygen content resulted in low intubation rates, low overall mortality, and a low number of patients who require oxygen after discharge. Although COVID-19 is asymptomatic to mild in about 80% of cases, about 15% of patients show a severe and about 5% a critical course, which is usually based on lung involvement with respiratory failure[1]. The first therapeutic recommendations therefore addressed hypoxemia in particular with the aim of keeping oxygen saturation above at least 90% [2] . Some authors even advise caution against the use of high-flow oxygen administration (NHF) and non-invasive ventilation (NIV) in acute hypoxemic respiratory insufficiency in the context of COVID-19 and call for early intubation [3] , and some researchers even recommend intubation and invasive ventilation already if the Horovitz index [4] is 200 or lower [5] . In general, hypoxemia is an accepted indication for intubation in Covid 19 patients [6] disease [9] . The prognosis of invasively ventilated Covid 19 patients however is poor and mortality ranges somewhere around 50 % and higher, especially in older patients [10] [11] [12] . The fact that there is a large discrepancy between oxygen saturation and the extent of dyspnoea has given rise to the term 'happy hypoxemia' [13] in Covid 19 patients. The pathophysiological mechanisms of this phenomenon are being discussed currently [13] [14] [15] [16] [17] as well as the impact of happy hypoxemia on respiratory management [14] [18] . A recent Cochrane review did not find evidence, that higher oxygen targets benefit patients with respiratory failure [19] . Hypoxemia can either be caused by intrapulmonary shunting or ventilation-perfusion mismatch which in Covid 19 is mainly caused by diffusion impairment. Only the latter is responsive to supplemental oxygen [20] . Dyspnoea on the other hand poorly correlates to hypoxemia [21] . In the presence of inflammatory diseases (such as Sars-Cov-2 infections), hypoxemia is frequently being caused by other mechanisms such as stimulation of irritant, stretch, and J receptors [22] or activation of respiratory muscles [23] . Focusing on tissue hypoxia oxygen delivery (DO2), determined by oxygen content (CaO2) and cardiac output (CO) is crucial. Critical values for CaO2 with signs of anaerobic metabolism occur in animal models at levels below 9 mlO2/dl blood, which corresponds to an oxygen saturation of approximately 50% at normal haemoglobin levels and normal cardiac output [24] . Experiments in healthy humans have shown, that the critical level for oxygen content is lower than 6.6 (ml/dl) [25] . In particular lung tissue is vulnerable to oxygen concentrations of more than 21% and it is well known that oxygen per se is toxic if given in high concentrations an can cause ARDS in animal models [26] .This leads to the question, if a higher tolerance of hypoxemia and a preferred use of non-invasive respiratory support instead of intubation and decision making based on the clinical presentation as previously suggested should be preferred [18] and can improve outcome in Covid 19 patients. Based on these considerations we analysed the data of all hypoxemic Covid 19 patients in two hospitals that had previously agreed on such a protocol for the treatment of respiratory failure in COVID-pneumonia. Respiratory support should be given in the following escalating sequence (figure 1). Escalation to the next level was made if the patients clinical work of breathing required the next level of support or the oxygen content was determined to be below 9 ml/dl. Hypoxemia per se was not an indication to escalate (permissive hypoxemia). Patients had to be primarily admitted to one of the investigational sites. Patients who were transferred from other hospitals with prior treatment (e.g. who were already intubated) were excluded. Patients had to be Sars-CoV-2 PCR positive and had to have infiltrates on conventional chest X-ray or CT scan. Only patients with an oxygen saturation (SaO2) of less than 93 % were included into the analysis. All patients were treated in an intermediate care or intensive care setting with continuous monitoring of oxygen saturation and heart rate by pulse oximetry. Patients were seen at least daily by a senior physician and laboratory tests were done at least every other day. Respiratory therapists were readily available to deliver respiratory support. We identified a total of 78 patients who met the inclusion criteria (26 from facility 1 and 52 from facility 2). Mean hospital length of stay was 14.5 ± 13.5 days. Basic demographic data and pre-existing comorbidities are shown in For further analysis we grouped patients according to the maximal respiratory treatment as shown in figure 1. This group distribution is shown in figure 2 . The lowest reported oxygen saturation within these groups is shown in figure 3 . The lowest reported Horovitz index is shown in Figure 4 . The lowest measured oxygen content is shown in figure 5 . Laboratory values according to maximal treatment is shown in PO 2 nadir (mmHg) 54.5 ± 11 47.8 ± 10.5 45.9 ± 6.8 Table 2 : Demographic, physiological and laboratory data according to treatment groups. LOS = length of (hospital) stay, SaO2 = oxygen saturation, RR = blood pressure, LDH = lactate dehydrogenase, BNP = brain natriuretic peptide, CRP = C-reactive protein, PCT = procalcitonin, PO 2 = partial pressure of oxygen, nadir = lowest measured value, max = maximal measured value. Number in brackets indicate significant differences to the respective column (p< 0.05) All patients received beta-lactam antibiotics, 97.4 % of patients received an additional macrolide. Systemic anticoagulation was given in 88.5 % of patients. Since our data were collected before data from the Recovery trial were published [27] , dexamethasone was not given as the standard of care. Outcome, respectively respiratory treatment on discharge, is shown in figure 6 . The overall mortality was 7.7 %, the mortality rate of intubated patients was 50 %. The two patients who died on oxygen treatment were 86 and 96 years of age and had declared to refuse any form of respiratory support beyond oxygen administration in their living will. Reasons for intubation in eight patients were septic shock on admission in one patient, cardiac arrest due to AV-block 3 in one patient and NIV failure according to our protocol in six patients. Our escalation protocol of respiratory support measures that was based on the clinical presentation and oxygen content rather than on markers of oxygenation or the Horovitz index resulted in an intubation rate of only 10.3 % and an overall mortality of 7.7 %. Our mortality rate of 50 % in intubated patients is comparable to previous published data [10] [11] [12] . The overall mortality of patients hospitalized for Sars-CoV-2 infections in Germany is 22% [11] and is thus much higher than in our study in which only hypoxemic (see table 2 ) indicating, that the decision to intubate was probably done more progressively. ICU survival rates were 44 % in ventilated and 35 % in not ventilated patients and thus were much higher than the rate we reported (7.7%). Burns and co-workers found an improved survival when NIV was given to frail patients who were not deemed appropriate for invasive mechanical ventilation and proposed a general integrated escalation strategy of noninvasive respiratory therapies to avoid intubation [29] . Patel et al. worked with a respiratory escalation scheme in moderate to severe hypoxemic Covid 19 patients, that was comparable to ours [30] . Their decision to intubate was also based on clinical presentation but the oxygen saturation goal was 94 % and the ratio of intubated patients was 36 %. Our protocol did not call for an oxygen saturation goal, which might explain the lower intubation rate of 10.3 %. [31] . The patient's well tolerance of hypoxemia has led to the term 'happy hypoxemia' [13] . Hypoxemia hardly causes dyspnoea [21] , and dyspnoea is more related to hypercapnia, acidosis [32] or activation of the respiratory muscles [23] . Hypoxemia as measured by arterial blood gas analysis or pulse oximetry does not equal tissue hypoxia. Oxygen delivery to the cells is being determined by the oxygen content Elevated body temperature (fever) as seen in our patients shifts the oxygen dissociation curve to the right which facilitates the release of oxygen in the periphery [33] . A lack of oxygen on the cellular level does not occur until the oxygen delivery has decreased to 25% of the normal value [34] . In animal models anaerobic metabolism occurred if the oxygen content fell below 9 ml/dl [24] . Lieberman and co-workers had shown, that lowering the oxygen content to as low as 6.6 ml/dl did not cause signs of anaerobic metabolism in healthy volunteers [25] . Our threshold of 9 ml/dl appeared to be safe in our patient cohort. Based on these considerations, the clinical importance of hypoxemia should not be overestimated especially since invasive ventilation might correct hypoxemia short term but may inflict ventilator associated lung injury [35] or oxygen induced ARDS [26] . A more restrictive use of invasive mechanical ventilation and oxygen as suggested recently [18] , might be advised. Our data suggest that such a strategy is more beneficial for Covid 19 patients. We observed the typical laboratory abnormalities as seen in previous investigations [30] [36] . Previous investigations have shown, that there is great potential to recover from Covid 19 with very little sequelae [37] . It should be particularly emphasized that the majority (93%) of the patients who survived could be discharged without oxygen. Only four patients treated with NHF/CPCP/NIV required oxygen on discharge and one patient who was intubated Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected Staff safety during emergency airway management for COVID-19 in Hong Kong Withdrawal from positive end-expiratory pressure German recommendations for critically ill patients with COVID-19 Covid-19 in Critically Ill Patients in the Seattle Region -Case Series Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study High-Flow, Noninvasive Ventilation and Awake (Nonintubation) Proning in Patients With Coronavirus Disease 2019 With Respiratory Failure Clinical Course and Outcomes of Severe Covid-19: A National Scale Study Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study Case Fatality Rates for COVID-19 Patients Requiring Invasive Mechanical Ventilation: A Meta-analysis The mystery of the pandemic's 'happy hypoxia The pathophysiology of 'happy' hypoxemia in COVID-19 Misconceptions of pathophysiology of happy hypoxemia and implications for management of COVID-19 Acute Vascular Distress Syndrome" in Patients with COVID-19 Why COVID-19 silent hypoxemia is baffling to physicians Basing respiratory management of COVID-19 on physiological principles Oxygen targets in the intensive care unit during mechanical ventilation for acute respiratory distress syndrome: a rapid review Ventilatory failure, ventilator support, and ventilator weaning Impact of hypobaric flight simulation on walking distance and oxygenation in COPD patients Principles and practice of intensive care monitoring. Mcgraw-Hill Professional An official ATS clinical policy statement: Congenital central hypoventilation syndrome -Genetic basis, diagnosis, and management Mixed venous oxygen saturation and biochemical parameters of hypoxia during progressive hypoxemia in 10-to 14-day-old piglets Critical oxygen delivery in conscious humans is less than 7.3 ml O2 · kg-1 · min-1 One hundred percent oxygen lung injury in adult baboons Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: A multicentric study in Germany Improved survival following ward-based non-invasive pressure support for severe hypoxia in a cohort of frail patients with COVID-19: Retrospective analysis from a UK teaching hospital Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: A two-period retrospective case-control study An official American thoracic society statement: Update on the mechanisms, assessment, and management of dyspnea The effect of temperature on the dissociation curve of blood Identification of the Critical Oxygen Delivery for Anaerobic Metabolism in Critically III Septic and Nonseptic Humans Critical Care Medicine Ventilator-Induced Lung Injury Clinical Characteristics of 138 Hospitalized Patients with Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical course and outcomes of 3,060 patients with coronavirus disease 2019 in Korea